Aldeyra Therapeutics (ALDX) Change in Account Payables (2013 - 2026)
Aldeyra Therapeutics (ALDX) posted Change in Account Payables of -$17105.0 for Q1 2026, down 111.79% on a QoQ basis from $145038.0 in Q4 2025, and down 110.32% year-over-year from $165693.0 in Q1 2025.
Aldeyra Therapeutics (ALDX) Change in Account Payables (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics' Change in Account Payables history runs 14 years deep, the most recent figure standing at -$17105.0 for Q1 2026.
- Quarterly Change in Account Payables fell 110.32% year-over-year to -$17105.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$204790.0 (down 411.01% YoY) and the FY2025 annual result came in at -$21992.0, up 98.1% from the prior year.
- Change in Account Payables was -$17105.0 for Q1 2026 at Aldeyra Therapeutics, down from $145038.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.4 million in Q1 2022 and bottomed at -$1.2 million in Q4 2022.
- A 5-year average of -$51667.4 and a median of -$23622.0 in 2023 frame the typical range for Change in Account Payables.
- Peak annual rise in Change in Account Payables reached 2742.12% in 2025, while the deepest fall reached 1405.01% in 2025.
- Aldeyra Therapeutics' Change in Account Payables stood at -$1.2 million in 2022, then soared by 192.97% to $1.1 million in 2023, then plunged by 100.59% to -$6466.0 in 2024, then soared by 2343.09% to $145038.0 in 2025, then tumbled by 111.79% to -$17105.0 in 2026.
- Business Quant data shows ALDX's Change in Account Payables at -$17105.0 in Q1 2026, $145038.0 in Q4 2025, and -$1.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -42.19 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 16.86 Mn |
| 10 | Aldeyra Therapeutics | 95.00 Mn | 95.00 Mn | - | -17,105.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17,105.00 |
| Mar 31, 2026 | -17,105.00 |
| Dec 31, 2025 | 145,038.00 |
| Dec 31, 2025 | 145,038.00 |
| Sep 30, 2025 | -1.02 Mn |
| Sep 30, 2025 | -1.02 Mn |
| Jun 30, 2025 | 683,384.00 |
| Jun 30, 2025 | 683,384.00 |
| Mar 31, 2025 | 165,693.00 |
| Mar 31, 2025 | 165,693.00 |
| Dec 31, 2024 | -6,466.00 |
| Dec 31, 2024 | -6,466.00 |
| Sep 30, 2024 | -67,515.00 |
| Sep 30, 2024 | -67,515.00 |
| Jun 30, 2024 | -25,865.00 |
| Jun 30, 2024 | -25,865.00 |
| Mar 31, 2024 | -1.06 Mn |
| Mar 31, 2024 | -1.06 Mn |
| Dec 31, 2023 | 1.09 Mn |
| Dec 31, 2023 | 1.09 Mn |